Pin1 promotes degradation of Smad proteins and their interaction with phosphorylated tau in Alzheimer's disease

Neuropathology and Applied Neurobiology

Volumn 40, Issue 7, 2014, Pages 815-832

  Ueberham, Uwe ^a   Rohn, Susanne ^a   Ueberham, Elke ^b   Wodischeck, Susanne ^a   Hilbrich, Isabel ^a   Holzer, Max ^a   Brückner, Martina K ^a   Gruschka, Hildegard ^a   Arendt, Thomas ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b FRAUNHOFER INSTITUTE FOR CELL THERAPY AND IMMUNOLOGY   (Germany)

Author keywords

Alzheimer's disease; Neurodegeneration; Neurofibrillary tangles; Pin1; Smad2; Smad3; Tau

Indexed keywords

NIMA-INTERACTING PEPTIDYLPROLYL ISOMERASE; PEPTIDYLPROLYL ISOMERASE; SMAD PROTEIN; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; FEMALE; HIPPOCAMPUS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PROTEIN DEGRADATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; PEPTIDYLPROLYL ISOMERASE; PHOSPHORYLATION; PROTEOLYSIS; SMAD PROTEINS; TAU PROTEINS;

EID: 84911116982     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12163     Document Type: Article

References (54)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 239-259
2. Gertz HJ, Xuereb J, Huppert F, Brayne C, McGee MA, Paykel E, Harrington C, Mukaetova-Ladinska E, Arendt T, Wischik CM. Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease. Acta Neuropathol (Berl) 1998; 95: 154-158
3. Braak H, Braak E. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol 1996; 92: 197-201
4. Holzer M, Holzapfel HP, Zedlick D, Bruckner MK, Arendt T. Abnormally phosphorylated tau protein in Alzheimer's disease: heterogeneity of individual regional distribution and relationship to clinical severity. Neuroscience 1994; 63: 499-516
5. Gärtner U, Holzer M, Heumann R, Arendt T. Induction of p21ras in Alzheimer pathology. Neuroreport 1995; 6: 1441-1444
6. Arendt T, Holzer M, Stobe A, Gartner U, Luth HJ, Bruckner MK, Ueberham U. Activated mitogenic signaling induces a process of dedifferentiation in Alzheimer's disease that eventually results in cell death. Ann N Y Acad Sci 2000; 920: 249-255
7. Arendt T. Disturbance of neuronal plasticity is a critical pathogenetic event in Alzheimer's disease. Int J Dev Neurosci 2001; 19: 231-245
8. Arendt T. Alzheimer's disease as a loss of differentiation control in a subset of neurons that retain immature features in the adult brain. Neurobiol Aging 2000; 21: 783-796
9. Ueberham U, Ueberham E, Gruschka H, Arendt T. Altered subcellular location of phosphorylated Smads in Alzheimer's disease. Eur J Neurosci 2006; 24: 2327-2334
10. Lee HG, Ueda M, Zhu X, Perry G, Smith MA. Ectopic expression of phospho-Smad2 in Alzheimer's disease: uncoupling of the transforming growth factor-beta pathway? J Neurosci Res 2006; 84: 1856-1861
11. Chalmers KA, Love S. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies. J Neuropathol Exp Neurol 2007; 66: 1019-1026
12. Ueberham U, Hilbrich I, Ueberham E, Rohn S, Glockner P, Dietrich K, Bruckner MK, Arendt T. Transcriptional control of cell cycle-dependent kinase 4 by Smad proteins-implications for Alzheimer's disease. Neurobiol Aging 2012; 33: 2827-2840
13. Chalmers KA, Love S. Neurofibrillary tangles may interfere with smad 2/3 signaling in neurons. J Neuropathol Exp Neurol 2007; 66: 158-167
14. Baig S, van Helmond Z, Love S. Tau hyperphosphorylation affects Smad 2/3 translocation. Neuroscience 2009; 163: 561-570
15. Holzer M, Gartner U, Stobe A, Hartig W, Gruschka H, Bruckner MK, Arendt T. Inverse association of Pin1 and tau accumulation in Alzheimer's disease hippocampus. Acta Neuropathol (Berl) 2002; 104: 471-481
16. Dakson A, Yokota O, Esiri M, Bigio EH, Horan M, Pendleton N, Richardson A, Neary D, Snowden JS, Robinson A, Davidson YS, Mann DM. Granular expression of prolyl-peptidyl isomerase PIN1 is a constant and specific feature of Alzheimer's disease pathology and is independent of tau, Abeta and TDP-43 pathology. Acta Neuropathol 2011; 121: 635-649
17. Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU, Xu J, Kuang J, Kirschner MW, Fischer G, Cantley LC, Lu KP. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 1997; 278: 1957-1960
18. Ranganathan R, Lu KP, Hunter T, Noel JP. Structural and functional analysis of the mitotic rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell 1997; 89: 875-886
19. Lu KP. Pinning down cell signaling, cancer and Alzheimer's disease. Trends Biochem Sci 2004; 29: 200-209
20. Takahashi K, Uchida C, Shin RW, Shimazaki K, Uchida T. Prolyl isomerase, Pin1: new findings of post-translational modifications and physiological substrates in cancer, asthma and Alzheimer's disease. Cell Mol Life Sci 2008; 65: 359-375
21. Albert A, Lavoie S, Vincent M. A hyperphosphorylated form of RNA polymerase II is the major interphase antigen of the phosphoprotein antibody MPM-2 and interacts with the peptidyl-prolyl isomerase Pin1. J Cell Sci 1999; 112: 2493-2500
22. Morris DP, Phatnani HP, Greenleaf AL. Phospho-carboxyl-terminal domain binding and the role of a prolyl isomerase in pre-mRNA 3′-end formation. J Biol Chem 1999; 274: 31583-31587
23. Shaw PE. Peptidyl-prolyl cis/trans isomerases and transcription: is there a twist in the tail? EMBO Rep 2007; 8: 40-45
24. Hamdane M, Smet C, Sambo AV, Leroy A, Wieruszeski JM, Delobel P, Maurage CA, Ghestem A, Wintjens R, Begard S, Sergeant N, Delacourte A, Horvath D, Landrieu I, Lippens G, Buee L. Pin1: a therapeutic target in Alzheimer neurodegeneration. J Mol Neurosci 2002; 19: 275-287
25. Lippens G, Landrieu I, Smet C. Molecular mechanisms of the phospho-dependent prolyl cis/trans isomerase Pin1. FEBS J 2007; 274: 5211-5222
26. Theuerkorn M, Fischer G, Schiene-Fischer C. Prolyl cis/trans isomerase signalling pathways in cancer. Curr Opin Pharmacol 2011; 11: 281-287
27. Fischer G. Peptidyl-prolyl cis/trans isomerases and their effectors. Angew Chem Int Ed Engl 1994; 33: 1415-1436
28. Liou YC, Zhou XZ, Lu KP. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 2011; 36: 501-514
29. Zhou XZ, Lu PJ, Wulf G, Lu KP. Phosphorylation-dependent prolyl isomerization: a novel signaling regulatory mechanism. Cell Mol Life Sci 1999; 56: 788-806
30. Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G, Kullertz G, Stark M, Fischer G, Lu KP. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell 2000; 6: 873-883
31. Rudrabhatla P, Pant HC. Phosphorylation-specific peptidyl-prolyl isomerization of neuronal cytoskeletal proteins by Pin1: implications for therapeutics in neurodegeneration. J Alzheimers Dis 2010; 19: 389-403
32. Nakano A, Koinuma D, Miyazawa K, Uchida T, Saitoh M, Kawabata M, Hanai J, Akiyama H, Abe M, Miyazono K, Matsumoto T, Imamura T. Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J Biol Chem 2009; 284: 6109-6115
33. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV, Hyman BT. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012; 123: 1-11
34. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58: 1791-1800
35. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del TK. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404
36. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-486
37. Huth S, Lausier J, Gersting SW, Rudolph C, Plank C, Welsch U, Rosenecker J. Insights into the mechanism of magnetofection using PEI-based magnetofectins for gene transfer. J Gene Med 2004; 6: 923-936
38. Ueberham U, Zobiak B, Ueberham E, Bruckner MK, Boriss H, Arendt T. Differentially expressed cortical genes contribute to perivascular deposition in transgenic mice with inducible neuron-specific expression of TGF-beta1. Int J Dev Neurosci 2006; 24: 177-186
39. Rohn S, Suttkus A, Arendt T, Ueberham U. RVG peptide as transfection reagent for specific cdk4 gene silencing in vitro and in vivo. J Drug Target 2012; 20: 381-388
40. Ueberham U, Ueberham E, Bruckner MK, Seeger G, Gartner U, Gruschka H, Gebhardt R, Arendt T. Inducible neuronal expression of transgenic TGF-beta1 in vivo: dissection of short-term and long-term effects. Eur J Neurosci 2005; 22: 50-64
41. Ueberham U, Lange P, Ueberham E, Bruckner MK, Hartlage-Rubsamen M, Pannicke T, Rohn S, Cross M, Arendt T. Smad2 isoforms are differentially expressed during mouse brain development and aging. Int J Dev Neurosci 2009; 27: 501-510
42. Gillespie CS, Wilson R, Davidson A, Brophy PJ. Characterization of a cytoskeletal matrix associated with myelin from rat brain. Biochem J 1989; 260: 689-696
43. Lu PJ, Wulf G, Zhou XZ, Davies P, Lu KP. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein. Nature 1999; 399: 784-788
44. Marinescu VD, Kohane IS, Riva A. MAPPER: a search engine for the computational identification of putative transcription factor binding sites in multiple genomes. BMC Bioinformatics 2005; 6: 79
45. Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, Uchida T, Bronson R, Bing G, Li X, Hunter T, Lu KP. Role of the prolyl isomerase Pin1 in protecting against age-dependent neurodegeneration. Nature 2003; 424: 556-561
46. Thorpe JR, Mosaheb S, Hashemzadeh-Bonehi L, Cairns NJ, Kay JE, Morley SJ, Rulten SL. Shortfalls in the peptidyl-prolyl cis-trans isomerase protein Pin1 in neurons are associated with frontotemporal dementias. Neurobiol Dis 2004; 17: 237-249
47. Pastorino L, Sun A, Lu PJ, Zhou XZ, Balastik M, Finn G, Wulf G, Lim J, Li SH, Li X, Xia W, Nicholson LK, Lu KP. The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-beta production. Nature 2006; 440: 528-534
48. Wulf G, Finn G, Suizu F, Lu KP. Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat Cell Biol 2005; 7: 435-441
49. Shen ZJ, Braun RK, Hu J, Xie Q, Chu H, Love RB, Stodola LA, Rosenthal LA, Szakaly RJ, Sorkness RL, Malter JS. Pin1 protein regulates smad protein signaling and pulmonary fibrosis. J Biol Chem 2012; 287: 23294-23305
50. Matsuura I, Chiang KN, Lai CY, He D, Wang G, Ramkumar R, Uchida T, Ryo A, Lu K, Liu F. Pin1 promotes transforming growth factor-beta-induced migration and invasion. J Biol Chem 2010; 285: 1754-1764
51. Aragon E, Goerner N, Zaromytidou AI, Xi Q, Escobedo A, Massague J, Macias MJ. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev 2011; 25: 1275-1288
52. Lu KP, Hanes SD, Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996; 380: 544-547
53. Nakamura K, Greenwood A, Binder L, Bigio EH, Denial S, Nicholson L, Zhou XZ, Lu KP. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell 2012; 149: 232-244
54. Fanghanel J, Akiyama H, Uchida C, Uchida T. Comparative analysis of enzyme activities and mRNA levels of peptidyl prolyl cis/trans isomerases in various organs of wild type and Pin1-/- mice. FEBS Lett 2006; 580: 3237-3245